News: NXS Next Science Sees FY24 To Deliver Significant Topline Growth Across 3 Key Areas Of..., page-6

It's nice to hear from other believers.

I would caution though, that although they have issued guidance for US$36-40m revenue this financial year and cashflow positive by the end of the year, there remains significant risk (in my view) that they don't achieve this and consequently will need to return to the market for funding at a deep discount. I topped up my position in the 20s and low 30s, but offloaded these additional shares when the price got to 38c.

My advice to new shareholders is to wait and see how they progress this quarter. Give up a little upside for some certainty on the trajectory and the likelihood of achieving the guidance range. With revenue having gone backwards in Q1, the required revenue for the rest of the year to achieve guidance is significant.

Selling costs to date have always exceeded revenue. We need to see a marked change in this metric before this becomes a screaming buy.